Unnamed: 0
float64 0
1.06M
⌀ | title
stringlengths 1
512
| date
stringlengths 1
25
⌀ | stock
stringlengths 1
5
⌀ |
|---|---|---|---|
1,060,858 | Macquarie Initiates Coverage on Qunar Cayman Islands Limited at Neutral, Announces $30.00 PT | 2014-03-24 08:25:00-04:00 | QUNR |
1,060,859 | Benzinga's Top #PreMarket Losers | 2014-03-24 08:13:00-04:00 | QUNR |
1,060,860 | Aegis Capital Initiates Coverage on Qunar Cayman Islands Limited at Hold, Announces $36.00 PT | 2014-03-13 11:12:00-04:00 | QUNR |
1,060,861 | Qunar Cayman Islands Limited Reports Q4 EPS of $(0.18); Revenue of $41.50M | 2014-02-27 17:01:00-05:00 | QUNR |
1,060,862 | Goldman Discusses Battle in Chinese Internet Space: Upgrades Baidu, Downgrades Youku, Sohu | 2014-02-24 16:10:00-05:00 | QUNR |
1,060,863 | Qunar Cayman Islands Shares Moving Lower; May be Attributed to Negative Report Out of China | 2014-01-17 11:56:00-05:00 | QUNR |
1,060,864 | Qunar Mobile Air Ticket Bookings Exceed 60K in One Day | 2014-01-03 07:14:00-05:00 | QUNR |
1,060,865 | Goldman Sachs Initiates Coverage on Qunar Cayman Islands Limited at Neutral, Announces $20.00 PT | 2013-11-27 07:19:00-05:00 | QUNR |
1,060,866 | Barclays Initiates Coverage on Qunar Cayman Islands Limited at Overweight, Announces $30.00 PT | 2013-11-27 07:18:00-05:00 | QUNR |
1,060,867 | UPDATE: Deutsche Bank Initiates Coverage on Qunar, Awaiting Zhixin Impact | 2013-11-27 07:10:00-05:00 | QUNR |
1,060,868 | Deutsche Bank Initiates Coverage on Qunar Cayman Islands Limited at Hold, Announces $22.10 PT | 2013-11-27 06:29:00-05:00 | QUNR |
1,060,869 | UPDATE: Stifel Initiates Coverage on Qunar Cayman Islands on Fair Valuation | 2013-11-26 09:06:00-05:00 | QUNR |
1,060,870 | Stifel Nicolaus Initiates Coverage on Qunar Cayman Islands Limited at Hold | 2013-11-26 07:45:00-05:00 | QUNR |
1,060,871 | Shares of Qunar Down to $28.56, Hit Session High at $34.99 | 2013-11-01 12:17:00-04:00 | QUNR |
1,060,872 | Shares of Qunar Cayman Islands Resume, Stock Now Touching $32 | 2013-11-01 10:57:00-04:00 | QUNR |
1,060,873 | IPO for Qunar Cayman Islands Opens at $28.35 After Pricing at $15/Share, Stock Halted Immediately Following Open | 2013-11-01 10:50:00-04:00 | QUNR |
1,060,874 | Still Waiting on IPO Open of Qunar Cayman Islands Limited, NASDAQ Issues Update Saying Expecting to Open 'Shortly' | 2013-11-01 10:35:00-04:00 | QUNR |
1,060,875 | uniQure Highlights Presentations For ASGCT Meeting | 2020-05-14 07:12:00-04:00 | QURE |
1,060,876 | Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County. | 2020-05-13 12:49:00-04:00 | QURE |
1,060,877 | uniQure Q1 EPS $(0.630) Up From $(0.740) YoY | 2020-04-29 07:11:00-04:00 | QURE |
1,060,878 | uniQure Shares Volatile On Uptick In Volume; Hearing Cantor Fitzgerald Out With Positive Comments On Name | 2020-04-24 13:49:00-04:00 | QURE |
1,060,879 | Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. | 2020-04-07 07:48:00-04:00 | QURE |
1,060,880 | uniQure Reports Achievement Of Target Patient Dosing In HOPE-B Trial Of AMT-061 For Hemophilia B | 2020-03-26 07:30:00-04:00 | QURE |
1,060,881 | Shares of several healthcare companies are trading lower. Movement appears market-related as markets continue to dip amid the global coronavirus outbreak and OPEC failing to reach production agreement. | 2020-03-09 10:55:00-04:00 | QURE |
1,060,882 | Shares of several healthcare companies are trading lower. Movement appears market related as markets continue to dip amid the global coronavirus outbreak. | 2020-03-06 09:11:00-05:00 | QURE |
1,060,883 | Chardan Capital Maintains Buy on uniQure, Lowers Price Target to $105 | 2020-03-03 10:37:00-05:00 | QURE |
1,060,884 | uniQure And Gen-X Enter Research Collaboration And License Agreement For The Development Of Novel Synthetic Promoters | 2020-03-02 16:15:00-05:00 | QURE |
1,060,885 | The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns | 2020-02-07 07:32:00-05:00 | QURE |
1,060,886 | Cantor Fitzgerald Maintains Overweight on uniQure, Raises Price Target to $96 | 2020-01-23 08:15:00-05:00 | QURE |
1,060,887 | 10 Biotech M&A Targets Under The Scanner For 2020 | 2019-12-24 07:30:00-05:00 | QURE |
1,060,888 | A Perspective On Biopharma's Record M&A Run In 2019 | 2019-12-23 14:57:00-05:00 | QURE |
1,060,889 | uniQure Option Alert: Jan 17 $80 Calls Sweep (4) above Ask!: 575 @ $2.75 vs 1546 OI; Ref=$70.45 | 2019-12-18 12:55:00-05:00 | QURE |
1,060,890 | 10 Biggest Price Target Changes For Tuesday | 2019-12-10 08:42:00-05:00 | QURE |
1,060,891 | Mizuho Reiterates Buy on uniQure, Raises Price Target to $90 | 2019-12-10 08:01:00-05:00 | QURE |
1,060,892 | uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B at ASH 2019 | 2019-12-08 16:06:00-05:00 | QURE |
1,060,893 | The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling | 2019-12-07 08:35:00-05:00 | QURE |
1,060,894 | 63 Biggest Movers From Yesterday | 2019-12-04 05:15:00-05:00 | QURE |
1,060,895 | 40 Stocks Moving In Tuesday's Mid-Day Session | 2019-12-03 12:20:00-05:00 | QURE |
1,060,896 | The Gene Therapy Names Moving On The Audentes Buyout Deal | 2019-12-03 11:53:00-05:00 | QURE |
1,060,897 | UniQure shares are trading higher following the acquisition of gene therapy peer Audentes Therapeutics by Astellas. | 2019-12-03 10:56:00-05:00 | QURE |
1,060,898 | Benzinga's Top Upgrades, Downgrades For December 3, 2019 | 2019-12-03 09:35:00-05:00 | QURE |
1,060,899 | UniQure NV shares are trading higher after analysts from Goldman Sachs and Cowen & Co initiated coverage on the company's stock with bullish ratings. | 2019-12-03 07:52:00-05:00 | QURE |
1,060,900 | 19 Healthcare Stocks Moving In Tuesday's Pre-Market Session | 2019-12-03 07:46:00-05:00 | QURE |
1,060,901 | 22 Stocks Moving in Tuesday's Pre-Market Session | 2019-12-03 07:26:00-05:00 | QURE |
1,060,902 | Cowen & Co. Initiates Coverage On uniQure with Outperform Rating | 2019-12-03 07:12:00-05:00 | QURE |
1,060,903 | Goldman Sachs Initiates Coverage On uniQure with Buy Rating, Announces $98 Price Target | 2019-12-03 07:09:00-05:00 | QURE |
1,060,904 | Benzinga's Top Upgrades, Downgrades For November 5, 2019 | 2019-11-05 10:00:00-05:00 | QURE |
1,060,905 | uniQure Announces The Allowance Of New Patent Providing Further Protection Of The Padua And Padua-Related Variants Of Factor IX In Gene Therapy | 2019-11-05 07:18:00-05:00 | QURE |
1,060,906 | Credit Suisse Initiates Coverage On uniQure with Outperform Rating, Announces $76 Price Target | 2019-11-05 07:16:00-05:00 | QURE |
1,060,907 | uniQure Highlights Publication Of Interim Data From Phase IIb Clinical Trial Of Etranacogene Dezaparvovec | 2019-10-31 09:20:00-04:00 | QURE |
1,060,908 | Benzinga's Top Upgrades, Downgrades For October 11, 2019 | 2019-10-11 10:10:00-04:00 | QURE |
1,060,909 | Stifel Nicolaus Initiates Coverage On uniQure with Buy Rating, Announces $79 Price Target | 2019-10-11 07:12:00-04:00 | QURE |
1,060,910 | Benzinga's Top Upgrades, Downgrades For September 25, 2019 | 2019-09-25 10:04:00-04:00 | QURE |
1,060,911 | Bernstein Initiates Coverage On uniQure with Outperform Rating, Announces $73 Price Target | 2019-09-25 07:01:00-04:00 | QURE |
1,060,912 | Mizuho Initiates Coverage On uniQure with Buy Rating, Announces $67 Price Target | 2019-09-12 06:55:00-04:00 | QURE |
1,060,913 | 16 Healthcare Stocks Moving In Friday's Pre-Market Session | 2019-09-06 08:31:00-04:00 | QURE |
1,060,914 | 86 Biggest Movers From Yesterday | 2019-09-06 05:06:00-04:00 | QURE |
1,060,915 | uniQure Prices 4.9M Share Public Offering @$46/Share | 2019-09-06 04:45:00-04:00 | QURE |
1,060,916 | 55 Stocks Moving In Thursday's Mid-Day Session | 2019-09-05 12:27:00-04:00 | QURE |
1,060,917 | UniQure shares are trading lower after the company reported a $200 million common stock offering. | 2019-09-05 09:33:00-04:00 | QURE |
1,060,918 | The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug | 2019-09-05 08:12:00-04:00 | QURE |
1,060,919 | UniQure shares are trading lower after the company reported a $200 million common stock offering. | 2019-09-04 16:05:00-04:00 | QURE |
1,060,920 | uniQure Reports $200M Common Stock Offering | 2019-09-04 16:03:00-04:00 | QURE |
1,060,921 | uniQure Achieves Planned Enrollment In HOPE-B Pivotal Trial Of AMT-061 In Patients With Hemophilia B | 2019-09-03 07:08:00-04:00 | QURE |
1,060,922 | Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products. | 2019-08-13 11:53:00-04:00 | QURE |
1,060,923 | Benzinga's Top Upgrades, Downgrades For July 30, 2019 | 2019-07-30 09:59:00-04:00 | QURE |
1,060,924 | Guggenheim Downgrades uniQure to Neutral | 2019-07-30 06:42:00-04:00 | QURE |
1,060,925 | uniQure Q2 EPS $(0.83) Misses $(0.75) Estimate, Sales $2.47M Beat $1.46M Estimate | 2019-07-29 07:25:00-04:00 | QURE |
1,060,926 | uniQure Option Alert: Jan 17 $70 Calls Sweep (2) near the Ask: 600 @ $14.351 vs 19 OI; Earnings 8/7 Before Open [est] Ref=$68.48 | 2019-07-15 12:31:00-04:00 | QURE |
1,060,927 | Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs. | 2019-07-08 12:55:00-04:00 | QURE |
1,060,928 | uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061; Clinical Benefit and Tolerability Maintained in All Patients Through Up to 3.5 Years of Follow-up | 2019-07-06 07:36:00-04:00 | QURE |
1,060,929 | The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight | 2019-07-05 08:55:00-04:00 | QURE |
1,060,930 | The Week Ahead In Biotech: Pending Clinical Readouts In Focus | 2019-06-29 08:25:00-04:00 | QURE |
1,060,931 | 60 Biggest Movers From Yesterday | 2019-06-25 05:12:00-04:00 | QURE |
1,060,932 | 40 Stocks Moving In Monday's Mid-Day Session | 2019-06-24 12:35:00-04:00 | QURE |